174 related articles for article (PubMed ID: 16352928)
1. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Minami H; Ebi H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
[TBL] [Abstract][Full Text] [Related]
3. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs.
Baek IH; Lee BY; Kim MS; Kwon KI
Eur J Drug Metab Pharmacokinet; 2013 Dec; 38(4):295-9. PubMed ID: 23564503
[TBL] [Abstract][Full Text] [Related]
5. Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Nakajima M; Genda T; Suehira M; Satoh H; Miki A; Hori S; Sawada Y
Cancer Chemother Pharmacol; 2010 Oct; 66(5):969-72. PubMed ID: 20107800
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
Nishida M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
[TBL] [Abstract][Full Text] [Related]
7. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
[TBL] [Abstract][Full Text] [Related]
8. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
[TBL] [Abstract][Full Text] [Related]
9. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of capecitabine.
Reigner B; Blesch K; Weidekamm E
Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of capecitabine in breast cancer.
Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
[TBL] [Abstract][Full Text] [Related]
13. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
Br J Cancer; 2003 Mar; 88(5):782-7. PubMed ID: 12618890
[TBL] [Abstract][Full Text] [Related]
14. Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Shindoh H; Kawashima A; Shishido N; Nakano K; Kobayashi K; Horii I
J Toxicol Sci; 2006 Aug; 31(3):265-85. PubMed ID: 16960436
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
16. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
17. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
19. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Tsukamoto Y; Kato Y; Ura M; Horii I; Ishitsuka H; Kusuhara H; Sugiyama Y
Pharm Res; 2001 Aug; 18(8):1190-202. PubMed ID: 11587492
[TBL] [Abstract][Full Text] [Related]
20. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
